Driving reinvestment in R&D for antibiotics and advocating their responsible use

Summary

fiogf49gjkf0d
DRIVE-AB (Driving Reinvestment in R&D and Responsible Antibiotic Use) is a public-private consortium funded by the EU Innovative Medicines Initiative (IMI) with in-kind support from EFPIA partners (European Federation of Pharmaceutical Industries and Associations) equivalent to one third of the total funding awarded. This collaborative multinational project seeks to recommend options to governments and policy makers around the world to stimulate innovation and responsible use while ensuring global access to novel antibiotics to meet public health needs. DRIVE-AB will help to define what constitutes responsible antibiotic use, forecast future resistance trends to inform public health priorities and estimate the real value of new antibiotics based on the economic and health costs of growing antimicrobial resistance. The research results will feed into the development and testing of new alternative economic models to incentivise investment in antibacterial drug R&D. DRIVE-AB will quantitatively model and test the most promising models against both the attractiveness of the return and public health benefit.

Homepage

http://drive-ab.eu

Focus

Antibiotics, financing of research

Keywords

Antibiotics, financing of research

Cooperating institutions

fiogf49gjkf0d

Funding body

fiogf49gjkf0d

Associated researchers

fiogf49gjkf0d

Members

Domeij, Bengt